Genelux (GNLX) Cash from Financing Activities (2022 - 2026)

Genelux's (GNLX) quarterly Cash from Financing Activities came in at $18.5 million in Q1 2026, up 93.77% year-on-year from $9.6 million in Q1 2025, and up 6616.67% quarter-over-quarter from $276000.0 in Q4 2025.

Genelux (GNLX) Cash from Financing Activities (2022 - 2026) Analysis & Trends

Genelux's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $18.5 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 93.77% year-over-year to $18.5 million in Q1 2026; TTM through Mar 2026 was $18.9 million, a 49.54% decrease from a year earlier, with the FY2025 full-year figure at $9.9 million, down 65.29% from the prior year.
  • Cash from Financing Activities climbed to $18.5 million in Q1 2026 per GNLX's latest filing, from $276000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $27.7 million in Q2 2024 and bottomed at -$130000.0 in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $688000.0 (2024), against an average of $7.8 million.
  • Across the five-year window, Cash from Financing Activities jumped 11361.54% in 2023 and plunged 99.81% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $545000.0 in 2022, then retreated by 26.42% to $401000.0 in 2023, then tumbled by 77.31% to $91000.0 in 2024, then surged by 203.3% to $276000.0 in 2025, then soared by 6616.67% to $18.5 million in 2026.
  • Per Business Quant, the three latest GNLX Cash from Financing Activities figures stand at $18.5 million (Q1 2026), $276000.0 (Q4 2025), and $52000.0 (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 66,290.43 Bn 66,290.15 Bn - 30.14 Mn
2 Nanobiotix 1,914.07 Bn 1,914.01 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - 53,000.00
4 BeOne Medicines 467.97 Bn 463.18 Bn 1.35 Bn 68.63 Mn
5 Vertex Pharmaceuticals 122.73 Bn 115.48 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 70.42 Bn 61.67 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.82 Bn 62.82 Bn - -
8 Argenx Se 56.00 Bn 50.82 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.51 Bn 34.50 Bn 959.66 Mn 15.71 Mn
10 Genelux 128.48 Mn 128.48 Mn - 18.54 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 18.54 Mn
Mar 31, 2026 18.54 Mn
Dec 31, 2025 276,000.00
Dec 31, 2025 276,000.00
Jun 30, 2025 52,000.00
Jun 30, 2025 52,000.00
Mar 31, 2025 9.57 Mn
Mar 31, 2025 9.57 Mn
Dec 31, 2024 91,000.00
Dec 31, 2024 91,000.00
Jun 30, 2024 27.73 Mn
Jun 30, 2024 27.73 Mn
Mar 31, 2024 688,000.00
Mar 31, 2024 688,000.00
Dec 31, 2023 401,000.00
Dec 31, 2023 401,000.00
Sep 30, 2023 6.36 Mn
Sep 30, 2023 6.36 Mn
Jun 30, 2023 22.62 Mn
Jun 30, 2023 22.62 Mn